Chuck Royce's ADMA Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 1.23 M shares of ADMA Biologics, Inc. (ADMA) worth $22.52 M, representing 0.23% of the portfolio. First purchased in 2024-Q4, this short-term holding has been held for 5 quarters.
Based on 13F filings, Chuck Royce has maintained this position in ADMA for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 302,399 shares. Largest reduction occurred in Q2 2025, reducing 57,752 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's ADMA Biologics (ADMA) Holding Value Over Time
Track share changes against reported price movement
Quarterly ADMA Biologics (ADMA) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +302,399 | Add 32.44% | 1.23 M | $18.24 |
| Q3 2025 | +292,819 | Add 45.81% | 932,068 | $14.66 |
| Q2 2025 | -57,752 | Reduce 8.29% | 639,249 | $18.21 |
| Q1 2025 | +276,432 | Add 65.73% | 697,001 | $19.84 |
| Q4 2024 | +420,569 | New Buy | 420,569 | $17.15 |
Chuck Royce's ADMA Biologics Investment FAQs
Chuck Royce first purchased ADMA Biologics, Inc. (ADMA) in Q4 2024, acquiring 420,569 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held ADMA Biologics, Inc. (ADMA) for 5 quarters since Q4 2024.
Chuck Royce's largest addition to ADMA Biologics, Inc. (ADMA) was in Q4 2024, adding 420,569 shares worth $7.21 M.
According to the latest 13F filing for Q4 2025, Chuck Royce's firm, Royce & Associates Lp, owns 1,234,467 shares of ADMA Biologics, Inc. (ADMA), valued at approximately $22.52 M.
As of the Q4 2025 filing, ADMA Biologics, Inc. (ADMA) represents approximately 0.23% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in ADMA Biologics, Inc. (ADMA) was 1,234,467 shares, as reported at the end of Q4 2025.